Interleukin-6 in Rheumatoid Arthritis

Franco Pandolfi; Laura Franza; Valentina Carusi; Simona Altamura; Gloria Andriollo; Eleonora Nucera

doi:10.3390/ijms21155238

Interleukin-6 in Rheumatoid Arthritis

Franco Pandolfi, Laura Franza, Valentina Carusi, Simona Altamura, Gloria Andriollo, Eleonora Nucera

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Review article › peer-review

Abstract

The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.

Original language	English
Journal	Int J Mol Sci
Volume	21
Issue number	15
DOIs	https://doi.org/10.3390/ijms21155238
Publication status	Published - Jul 23 2020

Keywords

Antibodies, Monoclonal/pharmacology
Arthritis, Rheumatoid/drug therapy
Disease Progression
Humans
Interleukin-6/antagonists & inhibitors
Molecular Targeted Therapy
Signal Transduction/drug effects

Access to Document

10.3390/ijms21155238

Cite this

@article{2cd2c13c303c4090a8f795cb383b552c,

title = "Interleukin-6 in Rheumatoid Arthritis",

abstract = "The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.",

keywords = "Antibodies, Monoclonal/pharmacology, Arthritis, Rheumatoid/drug therapy, Disease Progression, Humans, Interleukin-6/antagonists & inhibitors, Molecular Targeted Therapy, Signal Transduction/drug effects",

author = "Franco Pandolfi and Laura Franza and Valentina Carusi and Simona Altamura and Gloria Andriollo and Eleonora Nucera",

year = "2020",

month = jul,

day = "23",

doi = "10.3390/ijms21155238",

language = "English",

volume = "21",

journal = "Int J Mol Sci",

issn = "1422-0067",

publisher = "NLM (Medline)",

number = "15",

}

TY - JOUR

T1 - Interleukin-6 in Rheumatoid Arthritis

AU - Pandolfi, Franco

AU - Franza, Laura

AU - Carusi, Valentina

AU - Altamura, Simona

AU - Andriollo, Gloria

AU - Nucera, Eleonora

PY - 2020/7/23

Y1 - 2020/7/23

N2 - The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.

AB - The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.

KW - Antibodies, Monoclonal/pharmacology

KW - Arthritis, Rheumatoid/drug therapy

KW - Disease Progression

KW - Humans

KW - Interleukin-6/antagonists & inhibitors

KW - Molecular Targeted Therapy

KW - Signal Transduction/drug effects

U2 - 10.3390/ijms21155238

DO - 10.3390/ijms21155238

M3 - Review article

C2 - 32718086

SN - 1422-0067

VL - 21

JO - Int J Mol Sci

JF - Int J Mol Sci

IS - 15

ER -

Interleukin-6 in Rheumatoid Arthritis

Abstract

Keywords

Access to Document

Fingerprint

Cite this